Alexion Pharmaceuticals (ALXN) : Premier Asset Managment scooped up 14,155 additional shares in Alexion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 84,420 shares of Alexion Pharmaceuticals which is valued at $10,715,431.Alexion Pharmaceuticals makes up approximately 2.62% of Premier Asset Managment’s portfolio.
Other Hedge Funds, Including , Leavell Investment Management reduced its stake in ALXN by selling 100 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 13,200 shares of ALXN which is valued at $1,675,476. Alexion Pharmaceuticals makes up approx 0.24% of Leavell Investment Management’s portfolio.Chevy Chase Trust Holdings boosted its stake in ALXN in the latest quarter, The investment management firm added 5,463 additional shares and now holds a total of 213,352 shares of Alexion Pharmaceuticals which is valued at $26,545,256. Alexion Pharmaceuticals makes up approx 0.15% of Chevy Chase Trust Holdings’s portfolio.Raymond James Trust N.a. boosted its stake in ALXN in the latest quarter, The investment management firm added 643 additional shares and now holds a total of 4,268 shares of Alexion Pharmaceuticals which is valued at $531,025. Alexion Pharmaceuticals makes up approx 0.04% of Raymond James Trust N.a.’s portfolio.
Alexion Pharmaceuticals opened for trading at $124.15 and hit $128 on the upside on Wednesday, eventually ending the session at $126.93, with a gain of 2.23% or 2.77 points. The heightened volatility saw the trading volume jump to 18,17,215 shares. Company has a market cap of $28,435 M.
On the company’s financial health, Alexion Pharmaceuticals reported $1.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $1.13. The company had revenue of $701.00 million for the quarter, compared to analysts expectations of $711.95 million. The company’s revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.Shares were Reiterated by SunTrust on Jul 13, 2016 to “Buy” and Lowered the Price Target to $ 197 from a previous price target of $220 .Shares were Upgraded by Credit Suisse on Jul 11, 2016 to ” Outperform” and Lowered the Price Target to $ 165 from a previous price target of $186 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.